Should Deceased Donors be Tested for vCJD?
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
The 1997 Bovine Spongiform Encephalopathy enquiry and the 2001 Hepatitis C litigation judgement set the UK scene for evoking the precautionary principle and the legal precedent that liability for defective transfusion products should not be dependent on medical negligence, but on the mere fact of defectiveness. Animal models indicate that vCJD in humans, with infection via the oral route, is likely to be associated with infectivity within the lymphoreticular system (LRS). This is likely to appear prior to the involvement of the central nervous system and thus infectivity is likely to be present in the LRS before the onset of clinical disease. A number of relevant epidemiological studies using LRS tissue have shown a low, but measurable, existence of the carrier state in vCJD. Two possible cases of transmission of the abnormal prion of vCJD by blood transfusion suggested that tissues might also transmit and that testing of LRS tissue from deceased potential tissue donors should be considered as a first measure towards the prevention of vCJD transmission by tissues designated for use in transplantation. A variety of different tissues could be used as representative of the LRS, but each is associated with problems of feasibility and practicality. Assays for vCJD have not been validated in the context of donor screening rather than epidemiological studies nor on deceased donors. However, given the number of vCJD cases in the UK, significant attention should be paid to the logistical, ethical, social and other issues associated with undertaking vCJD testing of tissue donors, with a view to introducing testing of deceased tissue donors for vCJD disease or latency.
- A v National Blood Authority 2001. TNLR No 200 (QB Div) (QL) (Burton J).
- BSE Inquiry Report 2000. www.bseinquiry.gov.uk.
- Bruce, M.E., McConnell, I., Will, R.G., Ironside, J.W. (2001) Detection of variant Creutzfeldt Jacob disease infectivity in extraneural tissues. Lancet 358: pp. 208-209 CrossRef
- Rapidly progressive dementia in a patient who received a cadaveric dura mater graft. MMWR 36: pp. 49-55
- Update: Creutzfeldt-Jakob disease in a patient receiving a cadaveric dura mater graft. MMWR 36: pp. 324-325
- Update: Creutzfeldt-Jakob disease in a second patient who received a cadaveric dura mater graft. MMWR 38: pp. 37-43
- Creutzfeldt-Jakob disease in patients who received a cadaveric dura mater graft. MMWR 42: pp. 560-563
- Clarke P. and Ghani A.C. 2005. Projections of the future course of the primary vCJD epidemic in the UK: Inclusion of subclinical infection and the possibility of wider genetic susceptibility. J. Roy. Soc. Interface doi:10.1098/rsif.2004.0017 (published on line).
- Clinical Incidents Panel 2001. The management of possible exposure to CJD through medical procedures: A Consultation Paper.pp 14.2www.dh.gov.uk/assetRoot/04/07/82/21/04078221.pdf.
- Council of Europe 2002. Guide to Safety and Quality Assurance for Organs, Tissues and Cells.
- Department of Health. Quarterly analysis of the incidence of vCJDwebsite www.dh.gov.uk.
- Duffy, P., Wolf, J., Collins, G., Devoe, A.G., Steeten, B., Cowen, D. (1974) Possible person to person transmission of Creutzfeldt-Jakob disease. New Engl. J. Med. 290: pp. 692-693
- `Guidelines for tissue bankingȁ9 in UK Blood Transfusion and Tissue Transplantation Guidelines.2002. Sixth Edition. The Stationary OfficeLondon.Available at http://www.transfusionguidelines.org.uk.
- Hill, A.F., Butterworth, R.J., Joiner, S., Jackson, G., Rossor, M.N., Thomas, D.J., Frosh, A., Tolley, N., Bell, J.E., Spencer, M., King, A., Al-Sharraj, S., Ironside, J.W., Lantos, P.L., Collinge, J. (1999) Investigation of variant Creutzfeldt-Jacob disease and other human prion diseases with tonsil biopsy samples. Lancet 353: pp. 183-189 CrossRef
- Hilton, D.A., Fathers, E., Edwards, P., Ironside, J.W., Zajick, J. (1998) Prion immunoreactivity in appendix before clinical onset of variant Creutzfeldt-Jacob disease. Lancet 352: pp. 703-704 CrossRef
- Hilton, D.A., Ghani, A.L., Conyers, L., Edwards, P., McCardle, L., Ritchie, D., Penney, M., Hegazy, D., Ironside, J.W. (2004) Prevalence of lymphoreticular prion protein accumulation in UK tissue samples. J. Pathol. 203: pp. 733-739 CrossRef
- Ironside, J.W., Hilton, D.A., Ghani, A., Johnston, N.J., Conyers, L., McCardle, L.M., Best, D. (2000) Retrospective study of prion-protein accumulation in tonsil and appendix tissues. Lancet 355: pp. 1693-1694 CrossRef
- Lindgren, P.G., Hagberg, H., Eriksson, B., Glimelius, B., Magnusson, A., Sundstrom, C. (1985) Excision biopsy of the spleen by ultrasonic guidance. Brit. J. Radiol. 58: pp. 853-857 CrossRef
- Llewelyn, C.A., Hewitt, P.E., Knight, R.S., Amar, K., Clousens, S., Mackenzie, J., Will, R.G. (2004) Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet 363: pp. 417-421 CrossRef
- Manuelidis, E.E., Angelo, J.N., Gorgacz, E.J., Kim, J.H., Manuelidis, L. (1977) Experimental Creutzfeldt-Jakob disease transmitted via the eye with infected cornea. New Engl. J. Med. 296: pp. 1334-1336 CrossRef
- Microbiological Safety of Blood Tissues for Transplantation, Department of Health: Guidance on the microbiological safety of human tissues and organs used in transplantation (NHS ExecutiveAugust 2000).
- Muraca, S., Chait, P., Connolly, B.L., Baskin, K.M., Temple, M.J. (2001) US-guided Core Biopsy of the Spleen in Children. Radiology 218: pp. 200-206
- Peden, A.H., Head, M.W., Ritchie, D.L., Bell, J.E., Ironside, J.W. (2004) Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet 364: pp. 527-529 CrossRef
- Sundar, S., Jha, T.K., Thakur, C.P., Engel, J., Sindermann, H., Fischer, C., Junge, K., Bryceson, A., Berman, J. (2002) Oral Miltefosine for Indian Visceral Leishmaniasis. New Engl. J. Med. 347: pp. 1739-1746 CrossRef
- Tabrizi, S.J., Elliott, C.L., Weismann, C. (2003) Ethical issues in human prion diseases. Brit. Med. Bull. 66: pp. 305-316
- Tange, R.A., Troost, D., Limburg, M. (1990) Progressive fatal dementia (Creutzfeldt-Jakob disease) in a patient who received homograft tissue for tympanic membrane closure. Eur. Arch. Otorhinolaryngol. 247: pp. 199-201 CrossRef
- Thadani, V., Penar, P.L., Partington, J., Kalb, R., Janssen, R., Schonberger, L.B., Rabkin, C.S., Prichard, J.W. (1988) Creutzfeldt-Jakob disease probably acquired from a cadaveric dura mater graft. J. Neurosurg. 69: pp. 766-769
- UK Blood Transfusion Tissue Transplantation Guidelines - vCJD Position Statement) http://www.transfusionguidelines.org.uk/docs/pdfs/position_statement_01_2005_02.pdf.
- Wadsworth, J.D.F., Joiner, S., Hill, A.F., Campbell, T.A., Desbruslais, M., Luthert, P.J., Collinge, J. (2001) Tissue distribution of protease resistant prion protein in variant Creutzfeldt Jakob disease using a highly sensitive immunoblotting assay. Lancet 358: pp. 171-180 CrossRef
- Warwick R. and Kearney J. 2004. Should tonsil be used as an analyte from cadaveric tissue donors to test for variant CJD? abstract, European Association for Tissue Banking EATB Prague.
- Should Deceased Donors be Tested for vCJD?
Cell and Tissue Banking
Volume 6, Issue 4 , pp 263-270
- Cover Date
- Print ISSN
- Online ISSN
- Kluwer Academic Publishers
- Additional Links
- Deceased tissue donor
- PrPsc (Prion Protein Scrapie)
- TSE (Transmissible Spongiform Encephalophy)
- Variant Creutzfeldt Jacob Disease (vCJD)
- Industry Sectors